Difference between revisions of "Gemcitabine (Gemzar)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
|||
| Line 9: | Line 9: | ||
*[http://chemocare.com/bio/gemcitabine.asp Gemcitabine (Gemzar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/gemcitabine.asp Gemcitabine (Gemzar) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/gemcitabine.asp Gemcitabine (Gemzar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/gemcitabine.asp Gemcitabine (Gemzar) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/gemcitabine-patient-drug-information Gemcitabine (Gemzar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/gemcitabine-patient-drug-information Gemcitabine (Gemzar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/gemcitabine-patient-drug-information Gemcitabine (Gemzar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/gemcitabine-patient-drug-information Gemcitabine (Gemzar) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 5/15/1996: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 15:35, 6 June 2013
General information
Class/mechanism: Pyrimidine analog; metabolized within cells to the active nucleoside forms: diphosphate (dFdCDP) and triphosphate (dFdCTP). Gemcitabine diphosphate inhibits ribonucleotide reductase, which catalyzes reactions that produce deoxynucleoside triphosphates for DNA synthesis. This inhibition of deoxynucleoside triphosphates helps gemcitabine triphosphate to compete with deoxycytidine triphosphate (dCTP) to be incorporated into DNA. DNA synthesis is halted, since only one additional nucleotide can be added to a DNA strand after gemcitabine is incorporated.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Gemcitabine (Gemzar) patient drug information (Chemocare)[3]
- Gemcitabine (Gemzar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/15/1996: Initial FDA approval